Remove Biobanking Remove Containment Remove Vaccine
article thumbnail

WORLD’S LARGEST BROWSABLE RESOURCE LINKING RARE PROTEIN-CODING GENETIC VARIANTS TO HUMAN HEALTH AND DISEASE

The Pharma Data

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). These genetic data have been paired with detailed health information to create this browsable resource. Biogen Safe Harbor.

article thumbnail

University of Melbourne reveals design of new infectious disease institute

Pharmaceutical Technology

The new AIID building will include a human infection challenge unit, high-containment facilities, a robotic biobanking facility, interview rooms, dry laboratories and spaces for community engagement and co-design work. It will be connected across multiple levels to the University of Melbourne’s Doherty Institute.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Collaboration between AbbVie, Biogen and Pfizer creates world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease

The Pharma Data

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. About the UK Biobank. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). For more than 170 years, we have worked to make a difference for all who rely on us.

article thumbnail

Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

The Pharma Data

The UK biobank released a further dataset on COVID-19 positive patients consisting of ~4,000 confirmed COVID-19 infected patients in November 2020. The Company also anticipates that the knowledge gained may provide valuable insight for the development of a broadly applicable infectious-disease susceptibility model in the future.